Abstract: The object is to provide an optical repeater, a manufacturing method of an optical repeater, and a relay method of an optical signal that can achieve a redundant configuration for a failure of a light source outputting an excitation light with a simple configuration. Light sources output lights. The optical amplification units amplify optical signals using excitation lights. An optical distribution unit branches the lights output from the light sources into two branched lights and distributes the branched lights in such a manner that each of the optical amplification units receives the branched light branched from the lights from two different light sources as the excitation light.

Abstract: The present invention aims to provide a heterocyclic compound having an AMPA receptor potentiator effect, which is expected to be useful as an agent for the prophylaxis or treatment of depression, Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.

Abstract: Abstract: The present invention refers to compounds of formula (I). The present invention also relates to compounds of formula (I) for use as G Protein coupled Receptor 139 (GPR139) antagonists in methods of medical treatment of e.g. depression, Alzheimer’s disease, schizophrenia, drug addiction, sleep disorders, pain, and attention deficit hyperactivity disorder. Exemplary compounds are e.g. 3-((1H-pyrazol-4-yl)methyl)-6?-(phenyl)-2H-(1,2?-bipyridin)-2-one derivatives and related compounds. The present description discloses the synthesis and characterisation of exemplary compounds, pharmacological data thereof, as well as exemplary tablet formulations comprising the compounds of the invention (e.g. page 83 to page 110; examples 1 to 33; reference example 1; test examples 1 and 2; tables 1 to 4).

Abstract: The present invention refers to compounds of formula (I). The present invention also relates to compounds of formula (I) for use as G Protein coupled Receptor 139 (GPR139) antagonists in methods of medical treatment of e.g. depression, Alzheimer's disease schizophrenia, drug addiction, sleep disorders, pain, and attention deficit hyperactivity disorder. Exemplary compounds are e.g. 1-(OH-pyrazol-4-yl)methyl)-3-(phenyl)-1,3-dihydro-2H-imidazol-2-one derivatives and related compounds. The present description discloses the synthesis and characterisation of exemplary compounds, pharmacological data thereof, as well as exemplary tablet formulations comprising the compounds of the invention (e.g. page 100 to page 143; examples 1 to 167; test examples 1 and 2; tables 1 to 4).

Abstract: The present invention aims to provide a heterocyclic compound having an AMPA receptor potentiator effect, which is expected to be useful as an agent for the prophylaxis or treatment of depression, Alzheimer’s disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.

Abstract: The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, pain, behavioral and psychological symptoms of dementia and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.

Abstract: An object is to provide an optical repeater that improves the fault tolerance of a plurality of excitation light sources while sharing the excitation light sources among a plurality of optical fibers. An optical repeater (100) includes excitation light sources (S1-S5), optical amplification units (A1-A5), and an optical distribution unit (10). The optical amplification units (A1-A5) amplify optical signals by using lights output from the excitation light sources (S1-S5). The optical distribution unit (10) includes a plurality of optical multiplexing/demultiplexing units. The optical distribution unit (10) is configured in such a manner that the lights from the four different excitation light sources in the excitation light sources (S1-S5) to be input to each of the light amplification units (A1-A5).

Abstract: In order to provide a compact and low power consumption optical repeater capable of amplifying a plurality of wavelength ranges, the optical repeater is provided with: an excitation means which generates excitation light in a single wavelength range; a first light amplification means which is excited by the excitation light and the amplification band of which is a first wavelength range; and a second light amplification means which is excited by the excitation light and the amplification band of which is a second wavelength range different from the first wavelength range.

Abstract: The present invention provides a compound having a glucosylceramide lowering action (e.g., promoting glucosylceramide metabolism, inhibition of glucosylceramide synthesis, promoting glucosylceramide catabolism, etc.), which is expected to be useful as an agent for the prophylaxis or treatment of lysosome diseases (e.g., Gaucher's disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.

Abstract: The present invention aims to provide a heterocyclic compound having an AMPA receptor potentiator effect, which is expected to be useful as an agent for the prophylaxis or treatment of depression, Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.

Abstract: The present invention provides a compound having a glucosylceramide synthase inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of lysosomal storage diseases (e.g., Gaucher's disease, Fabry's disease, GM1-gangliosidosis, GM2 activator deficiency, Tay-Sachs disease, Sandhoffs disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.

Abstract: The present invention provides a compound having a glucosylceramide synthase inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of lysosomal storage diseases (e.g., Gaucher's disease, Fabry's disease, GM1-gangliosidosis, GM2 activator deficiency, Tay-Sachs disease, Sandhoffs disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.

Abstract: The present invention aims to provide a heterocyclic compound having an AMPA receptor potentiator effect, which is expected to be useful as an agent for the prophylaxis or treatment of depression, Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

Abstract: To limit the number of excitation laser diodes (LDs) in an optical amplification device provided with a redundant excitation LD configuration, the optical amplification device is provided with: an excitation unit which outputs a plurality of excitation lights generated by a plurality of excitation light sources; a first distributing unit of which inputs are connected to the plurality of excitation light sources and which branches input lights and then outputs branched lights as a plurality of first distributed lights; a plurality of second distributing units of which inputs are connected to the first distributing unit and which combines and branches input lights and then outputs branched lights as a plurality of second distributed lights; and a plurality of gain mediums which are respectively excited by the plurality of second distributed lights.

Abstract: A heterocyclic compound that can have an antagonistic action on an NMDA receptor containing the NR2B subunit, and is expected to be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like is provided. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

Abstract: A repeater includes a pump light supplier configured to generate pump light; a first multiplexer configured to multiplex the pump light and a first wavelength division multiplexed optical signal; a second multiplexer configured to multiplex the pump light and a second wavelength division multiplexed optical signal; a first amplifier configured to amplify the first wavelength division multiplexed optical signal by use of the pump light; a second amplifier configured to amplify the second wavelength division multiplexed optical signal by use of the pump light; and a controller configured to control power of the pump light output to the first multiplexer and the second multiplexer, based on wavelength information about at least one of the first wavelength division multiplexed optical signal and the second wavelength division multiplexed optical signal.

Abstract: The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, pain, behavioral and psychological symptoms of dementia and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.

Abstract: An undersea repeater includes: a case housing therein a plurality of subunits; a plurality of optical amplifiers each being included as the subunit and having an amplifier that amplifies, based on excitation light, optical power of input signal light and outputs the amplified light; and an excitation light source that is included as the subunit, generates the excitation light, and outputs the split excitation light to each of the optical amplification units.

Abstract: The present invention provides a substituted pyrrolidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.